HPS Pharmacies wish to advise that Viatris is experiencing a supply interruption for Nitrostat® sublingual tablets as follows:
Nitrostat® 300 mcg
Glyceryl trinitrate (nitroglycerin) sublingual tablets
This product was approved for supply under Section 19A of the Therapeutic Goods Act 1989 following the discontinuation of the Australian registered brands. Supply under this approval has now ceased due to the introduction of Australian-registered Nitrostat® sublingual tablets.
Supplies of Nitrostat® 300mcg tablets (ARTG 438870) are expected to be available within the next 3-4 weeks.
Supplies of Nitrolingual® Pumpspray (glyceryl trinitrate 400mcg/metered dose) are not affected by this notice.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Viatris on 1800 274 276, or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise that Arrotex are anticipating a supply interruption for isoniazid tablets as follows:
Isoniazid Tablets
Isoniazid 100 mg
ARTG 13455
Supplies are expected to be impacted from late May 2026 and resolve by late June 2026.
An internationally registered alternative has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Please note that S19A products may have a longer lead time as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Arrotex Pharmaceuticals on 1800 195 055, or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to give notice that AstraZeneca is discontinuing Zoladex® 3.6mg Implant as follows:
Zoladex® Implant
Goserelin 3.6mg
ARTG 24368
Zoladex® 3.6mg Implant is set to be discontinued on 1st November 2026. Patients should consult their healthcare professional to discuss alternative treatment options.
The Zoladex® 10.8mg implant will remain available. This presentation is currently only registered and reimbursed in Australia for eligible prostate cancer patients. AstraZeneca is preparing an application to have the approved indications expanded to include breast cancer patients who are hormone receptor positive.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact AstraZeneca on 1800 805 342 or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise that Arrotex are experiencing a supply interruption for gliclazide 80mg tablets as follows:
APX-Gliclazide
Gliclazide 80 mg
ARTG 337479
Nidem
Gliclazide 80 mg
ARTG 79023
Normal supplies are expected to resume in mid-May 2026.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Arrotex Pharmaceuticals on 1800 195 055, or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise that Link Medical Products, in consultation with the Therapeutic Goods Administration (TGA), has issued a drug recall and product correction for their adrenaline pre-filled syringes, as follows:
Adrenaline-Link Pre-Filled Syringe
Adrenaline (epinephrine) acid tartrate 1:10 000 (1mg/10mL)
ARTG 210672
This market action follows a Product Defect Correction in 2024, related to reports of blocked syringe bores. Deaths have been reported in association with this issue.
The syringe barrel of the product has now been updated from a HYPAK syringe barrel to a HYLOK syringe barrel, eliminating the need for adaptors and enabling compatibility with additional connectors.
Recall: A recall is being undertaken for legacy HYPAK stock as the use of legacy stock with incompatible connectors or connectors without suitable adaptors may lead to blockages which can delay administration in emergency situations.
Affected batch: 0155765 (Exp: 31/05/2026) 
Please inspect your stock and quarantine all products from the affected batch. If HPS Pharmacies provide imprest management services to your facility, an HPS representative will inspect all stock stored in the designated imprest areas at the earliest opportunity. All affected products will be quarantined for return to the supplier, and HPS Pharmacies will arrange for replacement stock as soon as possible. An HPS Pharmacies staff member will contact senior medical and nursing staff if there is an immediate impact to your facility.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Link Healthcare on (02) 8401 9777, or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise that all suppliers are experiencing a supply interruption for aprepitant 165mg capsules as follows:
Aprepitant ARX
Aprepitant 165 mg
ARTG 309382
Aprepitant Lupin
Aprepitant 165 mg
ARTG 310220
Normal supplies are expected to resume in late September 2026. No direct alternatives are available. Alternative treatment options should be considered.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to give notice that GlaxoSmithKline Australia, in consultation with the Therapeutic Goods Administration (TGA), has issued a product correction for Flixotide® and Pavtide® Accuhalers:
| Product |
ARTG |
Affected batches |
| Flixotide® 100mcg |
58437 |
PA8S (Exp: 17/09/2027) |
| Flixotide® 250mcg |
58438 |
HM6D (Exp: 04/06/2028)
PA8V (Exp: 16/09/2028) |
| Flixotide® 500mcg |
58439 |
DT5H (Exp: 26/03/2028) |
| Pavtide® 100/50mcg |
208200 |
SJ5R (Exp: 24/10/2027) |
| Pavtide® 250/50mcg |
208201 |
SD3C (Exp: 22/10/2027) |
This product correction was initiated as some Accuhalers have not been automatically reloading when the device is rotated after use (as shown in the images below). If the dose is not manually reset, this may lead to a short-term flare-up of asthma symptoms. No defects have been observed in the market to date, and the products are not being recalled.
Patients should continue to use their device as prescribed. If a device does not automatically reset, patients should manually reset the starting position by pushing the lever down towards the mouthpiece prior to each dose (as shown in Figure 2). The sponsor advises patients to check that the dose counter has advanced to ensure the dose has been delivered.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact GlaxoSmithKline on 1800 033 109 or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to give notice that Sanofi-Aventis Australia, in consultation with the Therapeutic Goods Administration (TGA), has issued a product recall for diltiazem 60mg tablets as follows:
| Product |
ARTG |
Affected batches |
| Cardizem® 60mg |
73179 |
8149600 (Exp 04/2027)
8150154 (Exp 04/2027) |
| Vasocardol® 60mg |
73180 |
8151378 (Exp 10/2027) |
This product recall was initiated as a precautionary measure following detection of an impurity that is non-compliant with product registration.
Please inspect your stock and quarantine all products from the affected batches. If HPS Pharmacies provide imprest management services to your facility, an HPS representative will inspect all stock stored in the designated imprest areas at the earliest opportunity. All affected products will be quarantined for return to the supplier, and HPS Pharmacies will arrange for replacement stock as soon as possible. An HPS Pharmacies staff member will contact senior medical and nursing staff if there is an immediate impact to your facility.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Sanofi-Aventis Australia 1800 640 791, or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to give notice that Juniper Biologics is discontinuing Akynzeo® IV vials as follows:
Akynzeo® IV Vials
Fosnetupitant 235 mg + Palonosetron 250 microgram
ARTG 349310
Akynzeo® IV has been discontinued in January 2026. Akynzeo® capsules are not affected by this notice.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Juniper Biologics on 1800 281 493 or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise that Aspen Pharmacare is experiencing a supply interruption for Xylocaine® 1% DuoFit Theatre pack 20 mL ampoules as follows:
Xylocaine® 1% Ampoules
Lidocaine hydrochloride 200mg/20mL
ARTG 48361
This supply interruption is expected to resolve by mid-June 2026.
Alternative preparations of lidocaine 1% ampoules remain available. However, the packaging of these alternatives is not sterile (non-autoclaved and not individually wrapped) and should not be placed directly into the sterile field in theatre. Existing procedures for handling and administering of non-autoclaved products must be followed when handling alternative products during this shortage period.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Aspen Pharmacare on 1300 659 646 or your pharmacist at HPS Pharmacies.
Download PDF
